# Tobacco and Oral Health > Tobacco and oral health for BDS Community Dentistry: GATS India data, lesions from smokeless and smoked tobacco, COTPA 2003, cessation with 5 As. - Canonical URL: https://prepelephant.com/topics/bds/community-dentistry/tobacco-dental-ss - Exam / course: BDS · Subject: Community Dentistry - Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team - First published: 2026-10-02 - Last updated: 2026-10-02 - How to cite: "Tobacco and Oral Health", PrepElephant, https://prepelephant.com/topics/bds/community-dentistry/tobacco-dental-ss ## Direct answer Roughly every fourth Indian adult — 28.6% in GATS 2016–17, about 267 million people — uses tobacco, and uniquely among large countries the smokeless forms dominate: 21.4% chew against 10.7% who smoke. The dental chair therefore sits at the country's best screening point for tobacco harm: staining, smoker's palate, leukoplakia and oral submucous fibrosis announce themselves in the mouth years before cancer does, and a brief chairside intervention structured on the 5 As — ask, advise, assess, assist, arrange — plus knowledge of COTPA 2003 converts every dentist into both a cessation worker and, in the exam, a prepared candidate. ## What you must remember - GATS India 2016–17: overall use 28.6% (down from 34.6% in 2009–10), smokeless 21.4%, smoked 10.7%, average age of initiation about 18–19 years. - Indian products to name in vivas: bidi, cigarette; smokeless — gutkha, khaini, zarda, paan with tobacco, and mishri used as tooth powder. - Mucosal changes: tobacco-associated keratosis and leukoplakia, nicotinic stomatitis (smoker's palate, fissured and umbilicated papules), staining, black hairy tongue, dose-dependent periodontal destruction, and delayed wound healing. - Oral submucous fibrosis is driven by areca nut (arecoline, tannins) as much as by tobacco — gutkha combines both, and OSMF presents with burning, blanching, stiff mucosa, fibrotic bands and progressive trismus in a young user. - Potentially malignant disorders in order of transformation risk: erythroplakia highest, then non-homogeneous (speckled, verrucous, nodular) leukoplakia over homogeneous; an ulcer or lesion not healing in two to three weeks demands referral for biopsy. - Cessation pharmacotherapy: nicotine replacement (gum, patch, lozenge — gum 2 mg if first use is more than 30 minutes after waking, 4 mg otherwise), bupropion, varenicline; the national tobacco quitline 1800-11-2356 supports counselling. - Law: COTPA 2003 — smoking banned in public places (section 4), sale to and by minors and within 100 yards of educational institutions banned (section 5), trade regulation (section 6), and 85% pictorial warnings on packs since 2016 (section 7); electronic cigarettes were prohibited by a separate 2019 Act, and states ban gutkha under food safety law. ## A chairside cessation consult worked through Apply the 5 As to a 35-year-old who chews khaini ten times daily and has a white patch on his buccal mucosa. Ask: "Do you or did you use tobacco?" — documented at every visit, the step most often skipped. Advise: show him the lesion in a hand mirror and say, in one clear sentence, that chewing is causing this change and quitting now allows most lesions to regress; a visible lesion is the strongest cue to action a dentist owns. Assess dependence: ten pouches a day, first chew within half an hour of waking — high dependence, so pharmacotherapy is appropriate. Assist: set a quit date within two weeks, switch him to 4 mg nicotine gum on the time-to-first-use rule, rehearse triggers (post-meal, workplace breaks) with substitutes, and enlist a family member. Arrange follow-up at one to two weeks for support and gum tolerability, and review the patch at two to three weeks — persistence beyond that window is the referral trigger for biopsy, not more watching. Run honestly, this five-minute protocol is the community dentistry answer to the question the whole subject exists for. ## Where students slip Two slips repeat. First, attributing oral submucous fibrosis to tobacco alone: examiners expect areca nut — arecoline stimulates fibroblast collagen and impairs its breakdown — with gutkha's tobacco-plus-areca combination the typical culprit, and the trismus-progressing young patient the classic case. Second, writing "stop tobacco" as the entire cessation answer: the marks sit in the structure — 5 As for the willing, 5 Rs (relevance, risks, rewards, roadblocks, repetition) for the unwilling, and a named pharmacological option with its dosing logic. Law answers also thin out fast: candidates know COTPA exists but cannot attach section numbers to the public-place smoking ban or the 100-yard school rule, and they miss that the gutkha ban operates through food safety legislation treating tobacco-nicotine as prohibited food ingredients, not through COTPA at all. The "safe smokeless" myth deserves an explicit rebuttal in the exam: smokeless is not safe, merely differently lethal. ## Frequently asked questions ### What were the key GATS India 2016-17 findings? 28.6% of adults use tobacco — about 267 million people — with smokeless use (21.4%) double smoked use (10.7%), and average initiation in the late teens. ### Which oral lesion has the highest malignant transformation potential? Erythroplakia carries the highest risk, exceeding non-homogeneous leukoplakia, which in turn exceeds the homogeneous variety. ### What are the 5 As of brief tobacco intervention? Ask about tobacco use at every visit, advise quitting clearly, assess willingness and dependence, assist with a quit plan and pharmacotherapy, and arrange follow-up. ### Which statute regulates tobacco products in India? The Cigarettes and Other Tobacco Products Act, 2003, covering public-place smoking, sales to minors and near institutions, trade regulation and mandatory pictorial warnings. ### Why does oral submucous fibrosis figure in tobacco counselling? Because gutkha and similar products combine tobacco with areca nut, whose arecoline drives fibrosis, making OSMF a visible, preventable precursor condition in young chewers.